Emflaza (deflazacort)

SELF ADMINISTRATION - ORAL

Indications for Prior Authorization:
  • Treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older
Coverage Criteria:

For diagnosis of Duchenne muscular dystrophy (DMD):

  • Dose does not exceed 0.9 milligrams per kilogram of body weight once daily, AND
  • Diagnosis of Duchenne muscular dystrophy (DMD), AND
  • Patient is 2 years of age or older, AND
  • Prescribed by or in consultation with a neurologist who has experience treating children, AND
  • Patient has received genetic testing for a mutation of the dystrophin gene, AND
  • One of the following:
    • Documentation of a confirmed mutation of the dystrophin gene, or
    •  Muscle biopsy confirmed an absence of dystrophin protein, AND
  • Patient has had a trial and failure or intolerance to prednisone or prednisolone given at a dose of 0.75 mg/kg/day or 10 mg/kg/weekend, AND
  • One of the following:
    • Trial and intolerance (e.g., allergy to excipient) to generic deflazacort tablet (Applies to Brand Emflaza tablet only)
    • Trial and intolerance (e.g. allergy to excipient) to generic deflazacort oral suspension (Applies to Brand Emflaza suspension only)
       
Reauthorization Criteria:

For diagnosis of Duchenne muscular dystrophy (DMD):

  • Dose does not exceed 0.9 milligrams per kilogram of body weight once daily, AND
  • Patient has experienced a benefit from therapy (e.g., improvement or preservation of muscle strength), AND
  • One of the following:
    • Trial and intolerance (e.g., allergy to excipient) to generic deflazacort tablet (Applies to Brand Emflaza tablet only)
    • Trial and intolerance (e.g. allergy to excipient) to generic deflazacort oral suspension (Applies to Brand Emflaza suspension only)
Coverage Duration: 
  • Initial: 1 year
  • Reauthorization: 1 year
Additional Information: 
  • Emflaza Tablets: can be administered whole or crushed and taken immediately after mixing with applesauce.
  • Emflaza Oral Suspension: Use only the oral dispenser provided with the product.  After withdrawing the appropriate dose into the oral dispenser, slowly add the Emflaza Oral Suspension into 3 to 4 ounces of juice (except grapefruit juice) or milk and mix well. The dose should then be administered immediately. Discard any unused Emflaza Oral Suspension remaining after 1 month of first opening the bottle.
  • Dosing:
    • Approximately 0.9mg/kg/day once daily (round up to nearest possible dose when using tablets, or round up to nearest tenth of a mL when using suspension)
    • Concomitant moderate of strong CYP3A4 inhibitors (e.g., clarithromycin, fluconazole, diltiazem, verapamil): reduce dose to 1/3 of usual dose
    • Avoid use with moderate or strong CYP3A4 inducers
Policy Updates:
  • 5/1/2017 – New policy approved by P&T
  • 11/14/2023 – Updated age requirement, added additional criteria for initial review, added reauthorization criteria
  • 09/01/2024 – Addition of generic deflazacort tablets step through for Brand Emflaza tablets and suspension (P&T 08/20/2024) (P&T Meeting August)
References:
  1. Emflaza Prescribing Information. PTC Therapeutics, Inc. South Plainfield, NJ. Feb 2023. 
  2. Bushby K, Finkel R, Birnkrant DJ, et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77-93.
  3. Gloss D, Moxley RT 3rd, Ashwal S, Oskoui M. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(5):465-72.
  4. Griggs RC, Miller JP, Greenberg CR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016 Nov 15;87(20):2123-2131. 
  5. FDA Center for Drug Evaluation and Research. Medical Review [Application Number 208684Orig1s000, 208685Orig1s000]. FDA Web site. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208684,208685Orig1s000MedR.pdf. Accessed March 30, 2023. 

Last review date: September 1, 2024

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone